NEW YORK (GenomeWeb) – Luminex reported after the close of the market on Monday that its third quarter revenues rose 4 percent, driven by strength in the company's sample-to-answer molecular business.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $74.1 million, up from $71.2 million in the year-ago quarter, and short of the average Wall Street estimate for revenues of $74.4 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.